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ABSTRACT
Objectives: Detection rate of thyroid nodules is increasing with the use of new imaging modalities, 
especially in screening for malignancies. Positron emission tomography/computed tomography (PET/
CT)-positive thyroid nodules should be differentiated for malignancy to avoid unnecessary operations 
and further follow-up. Most trials evaluate the role of SUVmax, but there is no definitive information 
about the utility of Hounsfield unit (HU) values for prediction of malignancy. This study aimed to 
evaluate the HU values beside SUVmax for detecting malignancy risk of PET/CT-positive thyroid nodules. 
Subjects and methods: Results of 98 cancer patients who had fine needle aspiration biopsy (FNAB) 
for thyroid nodules detected on PET/CT between January 2011 and December 2015 were assessed. 
The FNABs and surgical pathological results were recorded. Results: FNABs revealed benign results 
in 32 patients (32.7%), malignant in 18 (18.4%), non-diagnostic in 20 (20.4%), and indeterminate in 28 
(28.5%). Twenty-four patients underwent thyroidectomy. The mean HU values were not significantly 
different in benign and malignant nodules (p = 0.73). However, the mean SUVmax was significantly 
higher (p < 0.001) in malignant ones. Area under curve (AUC) was 0.824 for SUVmax; the cut-off value 
was over 5.55 (p < 0.001), with 80% sensitivity, 84.5% specificity. Conclusions: Our current study 
demonstrated that HU value does not add any additional valuable information for discriminating 
between malignant and benign thyroid nodules. We also defined a SUVmax cut-off value of 5.55 for 
malignant potential of thyroid nodules detected on PET/CT. Arch Endocrinol Metab. 2018;62(4):460-5
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INTRODUCTION
T he detection rate of incidental thyroid nodules is increasing steadily due to the use 
of new radiological imaging modalities, such as 
18F-fluorodeoxyglucose (FDG) positron emission 
tomography/computed tomography (PET/CT). 
Uptake of 18F-FDG by the thyroid gland can be detected 
either diffusely or focally. Diffuse 18F-FDG uptake is 
usually due to benign processes, such as thyroiditis, 
while focal uptake can be due to either a benign or a 
malignant nodule. The detection rate of new thyroid 
nodules by PET/CT has been reported as 1-4% (1).
In the absence of a familial history of thyroid cancer or 
external beam radiation to the neck, the malignancy rates 
of thyroid nodules detected on PET/CT ranges between 
27.8-74%, whereas it is only 5-13% using ultrasound, CT, 
or magnetic resonance imaging (MRI) (1-3). Malignant 
cells tend to have higher glucose metabolism and thus 
may have positive 18F-FDG PET/CT scans. Although 
they tend to have higher maximum standardized uptake 
values (SUVmax) than benign nodules, the definitive cut-
off SUVmax for the prediction of a malignant thyroid 
nodule has not yet been defined (4).
The Hounsfield unit (HU), which was first 
introduced by Sir Godfrey Newbold Hounsfield, is 
used in CT scans and is a quantity proportional to the 
degree of X-rays that pass through or are absorbed by 
tissues (5). HU have since been used to evaluate and 
quantify tissues and fluids. The radiodensity of water 
is defined as 0, fat has a negative HU, and blood and 
other tissues have a positive HU, which are measured 
and reported in a variety of clinical approaches (6). 
Thus far, there is no clear information about the utility 
of HU values for the prediction of thyroid malignancy.
18F-FDG PET/CT-positive thyroid nodules tend 
to have higher rates of malignancy, which should 
be further investigated by thyroid ultrasonography 
to enlightment for the features of thyroid nodules. 
Clinically suspicious features of malignancy on thyroid 
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ultrasonography are hypoechogenicity, taller than 
wider appearance, irregular margins, hypervascularity, 
and microcalcifications (7). Many authorities, including 
the American Thyroid Association (ATA), recommend 
fine needle aspiration biopsy (FNAB) for exclusion of 
malignancy in thyroid nodules (8). Although FNAB is 
a simple, easily performed procedure for the detection 
of malignancy, in 15-30% of cases the results can be 
inconclusive. In most cases, repeat FNAB or diagnostic 
surgery needs to be carried out. More accurate and less 
invasive diagnostic approaches are required. The aim of 
this retrospective study is to evaluate the use of SUVmax 
and HU values for detecting the malignancy risk of 
18F-FDG PET/CT-positive thyroid nodules.
SUBJECTS AND METHODS
We retrospectively investigated the medical records 
of 98 patients with various cancers who had FNAB 
performed following the detection of 18F-FDG PET/
CT-positive thyroid nodules between January 2011 
and December 2015. None of the patients in our study 
group were evaluated for thyroid cancer as a primary 
site. The study was approved by our Institutional 
Review Board and Ethics Committee (Project number: 
KA16/23).
Medical records of all cancer patients with 18F-FDG 
PET/CT-positive thyroid nodules subjected to FNAB 
were extracted from the hospital database. The 18F-FDG 
PET/CT procedures were performed for the staging 
and/or follow-up of a cancer. The ultrasonographic 
features of these nodules were also noted.
The FNAB examinations were reported according 
to the Bethesda system for thyroid cytopathology (9). 
According to the Bethesda system, the cytopathology 
of thyroid nodules is separated into six groups: 
1) nondiagnostic or unsatisfactory, 2) benign, 3) 
atypia of undetermined significance or follicular lesion 
of undetermined significance, 4) follicular neoplasm 
or suspicious for a follicular neoplasm, 5) suspicious 
for malignancy, and 6) malignant. For this particular 
study, the FNABs were grouped as: 1) nondiagnostic, 
2) benign, 3) malignant and suspicious for malignancy, 
and 4) indeterminate. The indeterminate group 
included follicular neoplasm/suspected follicular 
neoplasm, or Hürthle cell neoplasm and atypia of 
undetermined significance subgroups. If more than one 
nodule was detected on a PET/CT scan, FNAB was 
performed on the nodule that had the higher SUVmax.
Together with SUVmax, HU values of the 
18F-FDG-
positive nodules were also calculated as an additional 
tool to predict malignancy during non-contrast CT 
scans taken together with PET imaging. Calculations 
were performed by the same experienced nuclear 
medicine physician. The ultrasonographic features and 
cytological and surgical results were compared with 
SUVmax and HU of 
18F-FDG PET/CT-positive nodules.
Whole body 18F-FDG PET/CT imaging
The patients were imaged using a dedicated PET/CT 
system (General Electric Medical System, Milwaukee, 
WI, USA). Patients fasted for at least 6 hours before 
intravenous administration of 2.5 MBq/kg 18F-FDG. 
Before 18F-FDG injection, blood glucose concentration 
was measured to confirm that patient levels were 
below 150 mg/dL. During the distribution phase, 
the patients were kept in the supine position in a quiet 
room. Combined image acquisition was performed 
60 minutes after 18F-FDG administration. First, an 
unenhanced CT scan (3.3 mm slice thickness) from 
the base of the skull to the inferior border of the pelvis 
was acquired using a standardized protocol (140 kV 
and 80 mA). The subsequent PET scan was obtained in 
three-dimensional mode from the base of the skull to 
the inferior border of the pelvis (6-7 bed positions, 2.5 
minutes per bed position) without repositioning the 
patient on the table. Patients were breathing shallowly 
while CT and PET images were acquired. Attenuation 
was corrected by the CT images obtained after 18F-FDG 
injection.
Thyroid lesions were analyzed semiquantitatively 
according to SUVmax values. The SUVmax was calculated 
automatically by software, as the ratio of the maximum 
tissue concentration of FDG (kBq/mL) in the 
structure delineated by the region of interest (ROI) 
to the activity injected per gram body weight of the 
patient (kBq/g). An 18F-FDG PET-CT-positive thyroid 
nodule was defined as a thyroid lesion with a calculated 
SUVmax greater than 2 MBq/kg FDG. The HU value 
was measured at the region of thyroid nodules marked 
by a non-contrast CT scan, and calculated as the mean 
value.
Statistical analysis
The data are expressed as means ± SD or as medians for 
data that do not fit a normal distribution. The baseline 
differences between the two groups were analyzed by 
Co
py
rig
ht
©
 A
E&
M
 a
ll r
ig
ht
s r
es
er
ve
d.
462
Hounsfield unit of thyroid nodules
Arch Endocrinol Metab. 2018;62/4
Student’s t-test. Pearson’s chi-square test, and Fisher’s 
exact test were used to compare the ratios between 
groups. The baseline differences between groups were 
also analyzed by the Kruskal-Wallis test and Mann-
Whitney U test. In this study, the cut-off value of 
SUVmax was defined. The sensitivity and specificity of 
the calculated SUVmax and the area under the receiver 
operating characteristic curve (AUROC) were also 
measured. A p value < 0.05 was considered statistically 
significant. All statistical analyses were performed using 
SPSS for Windows software (ver. 23.0; SPSS Inc., 
Chicago, IL, USA).
RESULTS
Ninety-eight patients were included in the study. The 
mean age of the study population (n = 98) was 57.6 
± 13.8 years, and 75 (76.5%) were women. The most 
common primary malignancy evaluated was breast 
cancer at 25.5%. Thirty-four patients had solitary 
nodules (34.7%); the remainder had two or more 
nodules. Mean maximum diameter of 18F-FDG PET/
CT-positive thyroid nodules was 22.5 ± 11.8 mm. The 
general characteristics and ultrasonographic features of 
the patients are shown in detail in Table 1.
Cytological examination of FNABs were reported as 
benign in 32 patients (32.7%), malignant in 18 (18.4%), 
nondiagnostic in 20 (20.4%), and indeterminate in 28 
(28.5%). Thyroidectomy was performed on 24 patients. 
One of 20 patients in the nondiagnostic FNAB group 
had surgery, and the nodule was found to be malignant. 
Two of 32 patients with benign cytology were 
operated on and were found to have benign nodules. 
Nine of 18 patients with malignant and suspicious for 
malignancy FNABs were operated on, and all operation 
specimens were found to be malignant. The remaining 
9 patients with malignant FNABs were not subjected 
to thyroidectomy because of their accompanying poor 
general health. Twelve of 28 patients with indeterminate 
FNABs were subjected to thyroidectomy; 6 of them 
were diagnosed as malignant, and the remaining were 
diagnosed as benign. The final pathological examination 
of 24 cases subjected to thyroidectomy revealed one 
patient with thyroid metastasis of primary cancer, one 
with anaplastic thyroid carcinoma, one with follicular 
carcinoma of thyroid, 13 patients with papillary 
carcinoma of thyroid, and the remaining eight were 
diagnosed as benign. These results are summarized in 
Figure 1.
Table 1. General characteristics of the patients, ultrasonographic features of 18F-FDG PET/CT positive nodules regarding FNAB results
Benign (n = 32) Malignant (n = 18) Indeterminated (n = 28) Non-diagnostic (n = 20) p value
Age (year) 56.6 ± 14.4 53.55 ± 20.93 57.42 ± 11.61 62.2 ± 10.5 0.15
Female (n, %) 27 (36%) 11 (14.6%) 21 (28%) 16 (21.4%) NS
Male 5 (21.7%) 7 (30.4%) 7 (30.4%) 4 (17.4%) NS
Type of nodule
Solid 24 (33.8%) 8 (11.3%) 21 (29.5%) 18 (25.4%) 0.39
Solid-cystic 4 (44.4%) 1 (11.1%) 2 (22.2 %) 2 (22.2%) 0.29
Size (max diam.mm) 22.03 ± 10.5 21.46 ± 13.73 21.93 ± 11.47 22.5 ± 12.71 0.65
Hypoechogenic 18 (32.7%) 14 (25.5%) 13 (23.6%) 10 (18.2%) 0.52
Hyperechogenic 1 (20%) 1 (20%) 2 (40%) 1 (20%) 0.67
Isoechogenic 10 (50%) 1 (5%) 6 (30%) 3 (15%) 0.27
Microcalcification 2 (25%) 1 (12.5%) 0 5 (62.5%) 0.034
Taller than wider 0 1 (33.3%) 2 (66.7%) 0 0.32
Vascularity 3 (30%) 3 (30%) 4 (40%) 0 0.23
NS: not significant.
98 Patients with FNAB Results
Non-diagnostic: 20 Patients
1 Operation
Result: 1 Malignant
Benign-32 Patients
2 Operations
Results: 2 Benign
Malignant-18 Patients
9 Operations
Results: 9 Malignant
lndeterminate: 8 Patients
12 Operations
Results: 6 Benign and
6 Malignant
Figure 1. The surgical outcomes of the patients who underwent 
thyroidectomy.
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When we evaluate FNAB and postoperative 
pathological results of nodules together, 38 of them 
were considered as benign (32 patients with benign 
FNAB results and 6 of 12 patients with indeterminate 
FNAB results who subjected to thyroidectomy) and 
25 of them were malignant (18 cases with malignant 
FNAB results and 6 cases with indeterminate FNAB 
results who subjected to thyroidectomy) and one 
with non-diagnostic FNAB result who subjected to 
thyroidectomy. The mean SUVmax was found to be 
significantly higher (p < 0.001) in malignant nodules 
than benign ones: 17.94 (min = 2.1, max = 82.2, 
median = 11.3, SD = 19.10) versus 4.68 (min = 2, 
max = 22.4, median = 3.3, SD = 4.02). The under the 
curve (AUC) was 0.824 for SUVmax; the cut-off value 
was over 5.55 (p < 0.001), with 80% sensitivity and 
84.5% specificity (ROC curve) (Figure 2). However, 
mean HU values of these malignant and benign thyroid 
nodules were not significantly different (p = 0.73), 50.5 
(min = 15, max = 91, median = 49, SD = 16.93) and 
43.9 (min = 12, max = 67, median = 51, SD = 17.25), 
respectively (Table 2). We also grouped the patients 
according to SUVmax cut-off level (5.55). We found 
that SUVmax was correlated to HU values in all patients 
(p = 0.03). The nodules that have higher SUVmax have 
higher HU values. However, when only benign and 
malignant nodules were evaluated, we did not find any 
correlations between SUVmax and HU values.
DISCUSSION
In this study, inquiring the malignancy risk of 18F-FDG 
PET/CT-positive thyroid nodules via using SUVmax and 
HU values, we found that SUVmax values of nodules 
with malignant pathology were higher. However, the 
HU values exhibited statistically insignificant difference.
The malignancy risk of thyroid nodules ranges 
between 5-15% (10), and the risk increases if they are 
detectable on PET/CT scans 27.8-74% (3). Although 
the prevalence varies widely, according to a recent 
meta-analysis, 34.8% of thyroid nodules detected 
by 18F-FDG PET/CT are malignant (11). Even 
though, only 24.5% of the cases were subjected to 
thyroidectomy due to their inconvenient general health 
conditions, keeping in accordance with the analysis 
above, the malignancy rate was 25.5% in our cohort. 
The use of the SUVmax as a semiquantitative parameter 
to discriminate between benign and malignant tumors 
has been suggested previously (12,13). This measure 
reflects the metabolic activity of the lesions and, in 
general, a higher SUVmax value may imply malignancy 
(14). One of the factors affecting SUVmax is the 
expression of glucose transporters, and thyroid cancer 
cells usually have increased GLUT-1 expression (12). It 
has also been suggested that the SUVmax is influenced 
by different grades of inflammation, blood flow, and 
the size of the malignant lesions (15). Because of the 
high risk of malignancy, it is important to identify 
malignant 18F-FDG-positive nodules and determine 
which patients require surgical intervention. However, 
there is inconsistent information about the diagnostic 
role of SUVmax values for determining malignancy. 
Some studies have shown no significant difference 
between the SUVmax values of benign and malignant 
thyroid nodules (16-18), whereas numerous others 
have suggested its usefulness for identifying malignant 
Table 2. SUV max and Hounsfield values of 18F-FDG PET/CT positive 
nodules regarding FNAB and postoperative pathological results
Benign (n = 38) Malignant (n = 25) p value
SUV max 4.68 ± 4.02
min = 2
max = 22.4
median = 3.3
17.94 ± 19.10
min = 2.1
max = 82.2
median = 11.3
< 0.001
Hounsfield 
Unit
43.9 ± 17.25
min = 12
max = 67
median = 51
50.5 ± 16.93
min = 15
max = 91
median = 49
0.73
SUV max: Maximum Standardized Uptake Value.
Figure 2. Receiver operating characteristic (ROC) curve of standardized 
uptake value (SUV max). The sensitivity and specifity in the prediction of 
malignant thyroid nodules.
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lesions (14,19,20). The importance of SUVmax and its 
definitive cut-off value for predicting malignancy have 
not yet been established among patients with 18F-FDG 
PET/CT-positive thyroid nodules. The cut-off value 
for SUVmax was found to be 5.55 in the current study, 
which is corroborated by a previous report (21). The 
inconsistent results in current medical literature may 
be due to differences in glucose metabolism among 
detected lesions and/or differences in tumor size. 
Accordingly, Kim and cols. reported no significant 
difference in SUVmax between malignant and benign 
thyroid nodules less than 1 cm in size (22). When the 
nodules in our study were categorized up to 1 cm size 
cut-off, there was no significant difference regarding 
SUVmax between malignant and benign nodules, as well.
To avoid unnecessary surgical operations and 
further investigations, an additional diagnostic tool 
besides SUVmax is required. Recently, Kim and cols. 
demonstrated that the HU values of thyroid nodules 
detected on 18F-FDG PET/CT scans were higher 
in malignant than benign ones, and the sensitivity, 
specificity, and accuracy of HU values were all higher 
than those of SUVmax (22). This is the only study 
proposing the use of HU value as a new parameter 
to classify the risk of malignancy of 18F-FDG PET/
CT-positive thyroid nodules. For confirmation, we 
calculated the HU values of thyroid nodules on non-
contrast CT in addition to SUVmax. There was no 
significant difference between mean HU value of benign 
and malignant thyroid nodules in our study. The HU 
measurement seems to have no additional value for the 
identification of malignant and benign thyroid nodules 
detected on PET/CT scans. Our finding is consistent 
with the study by Sayman and cols. (23), although 
conflicting with Kim’s study (22). Further studies are 
required to verify these results.
Our study has some limitations. The retrospective 
design is one of them. The other is the relatively low 
number of cases that were subjected to thyroidectomy 
in indeterminate and non-diagnostic groups. Only 
one of the 20 patients with nondiagnostic FNAB, and 
12 of the 28 patients with indeterminate FNAB, had 
thyroidectomy. The final pathological examination 
showed one malignancy in the former group, whereas 
6 cases exhibited thyroid malignancy following 
thyroidectomy in the indeterminate FNAB group. If all 
of the nondiagnostic and indeterminate results could 
have been confirmed by repeat FNAB or surgery, the 
results would have been surely higher. However, this 
was not possible due to the critical health condition 
of the patients (most of whom were metastatic). If 
the cut-off value for SUVmax of 5.55 was applied to 
nondiagnostic thyroid nodules, 9 of 20 patients would 
have been above that value. If the same cut-off was 
applied to the indeterminate patients who did not 
undergo operation, half of them would have been over 
that value. These probabilities do not necessarily mean 
that these nodules were malignant, but suggest that the 
nodules should have been evaluated further.
In conclusion, we defined an SUVmax cut-off value of 
5.55 and demonstrated its importance in determining 
the malignant potential of thyroid nodules. Most 
of the published research on the issue of thyroid 
incidentaloma detected at 18F-FDG/PET CT focus 
on the role of SUVmax and its potential role in the 
differentiation of malignant and benign thyroid lesions. 
Our study deals with the potential role of additional 
information obtained from the CT part of this imaging 
modality. The analysis of HUs of metabolically active 
thyroid nodules does not have any additional valuable 
information for discriminating between malignant and 
benign nodules.
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